Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT	165 women	Headache 13/82 (16%) with progestogen-releasing IUD 9/83 (11%) with oral medroxyprogesterone	P value not reported
RCT	165 women	Ovarian cyst 10/82 (13%) with progestogen-releasing IUD 2/83 (2%) with oral medroxyprogesterone	P value not reported
RCT	165 women	Vaginitis (bacterial) 9/82 (11%) with progestogen-releasing IUD 3/83 (4%) with oral medroxyprogesterone	P value not reported
RCT	165 women	Urinary tract infection 6/82 (8%) with progestogen-releasing IUD 3/83 (4%) with oral medroxyprogesterone	P value not reported
RCT	165 women	Acne 5/82 (6.1%) with progestogen-releasing IUD 5/83 (6.0%) with oral medroxyprogesterone	P value not reported
RCT	165 women	Hypertension 5/82 (6%) with progestogen-releasing IUD 1/83 (1%) with oral medroxyprogesterone	P value not reported
RCT	165 women	Sinusitis 5/82 (6%) with progestogen-releasing IUD 3/83 (4%) with oral medroxyprogesterone	P value not reported
RCT	165 women	Upper respiratory tract infections 5/82 (6%) with progestogen-releasing IUD 1/83 (1%) with oral medroxyprogesterone	P value not reported
RCT	165 women	Breast tenderness 4/82 (5%) with progestogen-releasing IUD 3/83 (4%) with oral medroxyprogesterone	P value not reported
RCT	165 women	Fatigue 4/82 (5%) with progestogen-releasing IUD 2/83 (2%) with oral medroxyprogesterone	P value not reported
RCT	165 women	Pelvic pain 4/82 (5%) with progestogen-releasing IUD 2/83 (2%) with oral medroxyprogesterone	P value not reported
RCT	165 women	Increased weight 4/82 (5%) with progestogen-releasing IUD 5/83 (6%) with oral medroxyprogesterone	P value not reported
RCT	165 women	Lower abdominal pain 3/82 (4%) with progestogen-releasing IUD 5/83 (6%) with oral medroxyprogesterone	P value not reported